EA201790189A1 - Способы лечения злокачественного новообразования с использованием замещенных пирролопиримидиновых соединений, композиции на их основе - Google Patents
Способы лечения злокачественного новообразования с использованием замещенных пирролопиримидиновых соединений, композиции на их основеInfo
- Publication number
- EA201790189A1 EA201790189A1 EA201790189A EA201790189A EA201790189A1 EA 201790189 A1 EA201790189 A1 EA 201790189A1 EA 201790189 A EA201790189 A EA 201790189A EA 201790189 A EA201790189 A EA 201790189A EA 201790189 A1 EA201790189 A1 EA 201790189A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- pyrropyrymidin
- numer
- substituted
- compositions
- compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
В настоящем документе предложены способы лечения или профилактики злокачественного новообразования, в частности, солидных опухолей и гематологических злокачественных новообразований, включающие введение индивиду, при необходимости, эффективного количества соединения формулы (I)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462024158P | 2014-07-14 | 2014-07-14 | |
PCT/US2015/040125 WO2016010886A1 (en) | 2014-07-14 | 2015-07-13 | Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201790189A1 true EA201790189A1 (ru) | 2017-11-30 |
Family
ID=55066196
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201790189A EA201790189A1 (ru) | 2014-07-14 | 2015-07-13 | Способы лечения злокачественного новообразования с использованием замещенных пирролопиримидиновых соединений, композиции на их основе |
Country Status (9)
Country | Link |
---|---|
US (2) | US9623028B2 (ru) |
EP (1) | EP3169686A4 (ru) |
JP (1) | JP2017520603A (ru) |
KR (1) | KR20170024120A (ru) |
CN (1) | CN106715427A (ru) |
AU (1) | AU2015289929A1 (ru) |
CA (1) | CA2955009A1 (ru) |
EA (1) | EA201790189A1 (ru) |
WO (1) | WO2016010886A1 (ru) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201216017D0 (en) | 2012-09-07 | 2012-10-24 | Cancer Rec Tech Ltd | Inhibitor compounds |
KR102048719B1 (ko) * | 2015-08-13 | 2019-11-26 | 베이징 한미 파마슈티컬 컴퍼니 리미티드 | Irak4억제제 및 이의 용도 |
AU2018287988A1 (en) * | 2017-06-20 | 2019-10-10 | Breast Cancer Now | Methods and medical uses |
GB201709840D0 (en) * | 2017-06-20 | 2017-08-02 | Inst Of Cancer Research: Royal Cancer Hospital | Methods and medical uses |
CA3086714A1 (en) * | 2017-12-28 | 2019-07-04 | Development Center For Biotechnology | Heterocycle compounds as tyro3, axl and mertk (tam) family of receptor tyrosine kinase inhibitors |
CN113574057A (zh) * | 2019-03-13 | 2021-10-29 | 株式会社沃若诺伊 | 杂芳基衍生物及包含其作为活性成分的药物组合物 |
CN111620878A (zh) * | 2020-06-10 | 2020-09-04 | 中国药科大学 | 吡咯并嘧啶类衍生物作为蛋白激酶抑制剂及其应用 |
AU2022367221A1 (en) * | 2021-10-12 | 2024-05-02 | Biosplice Therapeutics, Inc. | 7h-pyrrolo[2,3-d]pyrimidines and preparation as dyrk1a inhibitors |
Family Cites Families (76)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3507866A (en) | 1967-08-08 | 1970-04-21 | Merck & Co Inc | 1h - imidazo(4,5-b)pyrazin - 2 - one and processes for their preparation |
US3567725A (en) | 1968-11-20 | 1971-03-02 | Merck & Co Inc | Process for preparation of 1h-imidazo-(4,5-b)pyrazin-2-ones |
US4294837A (en) | 1980-03-28 | 1981-10-13 | Sterling Drug Inc. | 1,3-Dihydro-6-(pyridinyl)-2H-imidazo[4,5-b]pyridin-2-ones and -imidazo[4,5-b]pyridine-2-thiones and their cardiotonic use |
US4294836A (en) | 1980-03-24 | 1981-10-13 | Sterling Drug Inc. | 1,3-Dihydro-6-(pyridinyl)-2H-imidazo[4,5-b]pyridin-2-ones and -imidazo[4,5-b]-pyridine-2-thiones and their cardiotonic use |
US4317909A (en) | 1980-03-24 | 1982-03-02 | Sterling Drug Inc. | Preparation of 1,3-dihydro-5-(pyridinyl)-2H-imidazo[4,5-b]pyridin-2-ones |
US4309537A (en) | 1980-03-28 | 1982-01-05 | Sterling Drug Inc. | Production of imidazo[4,5-b]pyridin-2-ones or thiones |
GB8709448D0 (en) | 1987-04-21 | 1987-05-28 | Pfizer Ltd | Heterobicyclic quinoline derivatives |
JPS63275582A (ja) | 1987-05-02 | 1988-11-14 | Naade Kenkyusho:Kk | 2−アミノイミダゾ〔4,5−b〕ピリジン誘導体の製造方法 |
DD262026A1 (de) | 1987-07-10 | 1988-11-16 | Akad Wissenschaften Ddr | Verfahren zur herstellung von 4-substituierten 6-(pyrid-4-yl)-2,4-dihydro-1h-imidazo[4,5-b]pyrid-2-onen |
FR2643903A1 (fr) | 1989-03-03 | 1990-09-07 | Union Pharma Scient Appl | Nouveaux derives de benzimidazole, leurs procedes de preparation, intermediaires de synthese, compositions pharmaceutiques les contenant, utiles notamment pour le traitement des maladies cardiovasculaires, et des ulceres duodenaux |
US4963561A (en) | 1990-02-28 | 1990-10-16 | Sterling Drug Inc. | Imidazopyridines, their preparation and use |
TW274550B (ru) | 1992-09-26 | 1996-04-21 | Hoechst Ag | |
DE19601627A1 (de) | 1996-01-18 | 1997-07-24 | Bayer Ag | Heteroatomhaltige Cyclopentanopyridyl-Oxazolidinone |
US6031105A (en) | 1996-04-09 | 2000-02-29 | Pfizer Inc | Substituted pyridines |
KR100547929B1 (ko) | 1997-09-26 | 2006-02-02 | 젠타리스 게엠베하 | 세린/트레오닌 단백질 키나제 기능을 조절하기 위한 아자벤즈이미다졸계 화합물, 이의 제조방법 및 이를 포함하는 약제학적 조성물 |
ZA9810490B (en) | 1997-12-03 | 1999-05-20 | Dainippon Pharmaceutical Co | 2-Aryl-8-oxodihydropurine derivative process for the preparation thereof pharmaceutical composition containing the same and intermediate therefor |
JP2003146987A (ja) | 1999-05-31 | 2003-05-21 | Dainippon Pharmaceut Co Ltd | 2−アリールプリン−9−アセトアミド誘導体 |
JP3814125B2 (ja) | 1999-06-02 | 2006-08-23 | 大日本住友製薬株式会社 | 2−アリール−8−オキソジヒドロプリン誘導体からなる医薬 |
JP2002100363A (ja) | 2000-09-25 | 2002-04-05 | Mitsubishi Chemicals Corp | リチウム二次電池用正極材料、リチウム二次電池用正極及びリチウム二次電池 |
JP2002167387A (ja) | 2000-11-29 | 2002-06-11 | Dainippon Pharmaceut Co Ltd | 2−(7,8−ジヒドロ−8−オキソ−9h−プリン−9−イル)酢酸誘導体 |
JP2004520299A (ja) | 2000-12-12 | 2004-07-08 | ニューロジェン・コーポレーション | スピロ[イソベンゾフラン−1,4’−ピペリジン]−3−オン類及び3h−スピロイソベンゾフラン−1,4’−ピペリジン類 |
WO2002076954A1 (en) | 2001-03-23 | 2002-10-03 | Smithkline Beecham Corporation | Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases |
DE50207522D1 (de) | 2001-09-04 | 2006-08-24 | Boehringer Ingelheim Int | Neue dihydropteridinone, verfahren zu deren herstellung und deren verwendung als arzneimittel |
EP1438048A1 (en) | 2001-10-18 | 2004-07-21 | Boehringer Ingelheim Pharmaceuticals Inc. | 1,4-disubstituted benzo-fused urea compounds as cytokine inhibitors |
US7247621B2 (en) | 2002-04-30 | 2007-07-24 | Valeant Research & Development | Antiviral phosphonate compounds and methods therefor |
KR20050006221A (ko) | 2002-05-06 | 2005-01-15 | 제네랩스 테크놀로지스, 인코포레이티드 | C형 간염 바이러스 감염 치료용의 뉴클레오시드 유도체 |
AU2003299531A1 (en) | 2002-08-05 | 2004-06-07 | University Of Massachusetts | Compounds for modulating rna interference |
AU2003270701B2 (en) | 2002-10-31 | 2009-11-12 | Amgen Inc. | Antiinflammation agents |
BRPI0406809A (pt) | 2003-01-17 | 2005-12-27 | Warner Lambert Co | Heterociclos substituìdos de 2-aminopiridina como inibidores da proliferação celular |
CN100537570C (zh) | 2003-02-26 | 2009-09-09 | 贝林格尔英格海姆法玛两合公司 | 二氢蝶啶酮、其制法及作为药物制剂的用途 |
GB2400101A (en) | 2003-03-28 | 2004-10-06 | Biofocus Discovery Ltd | Compounds capable of binding to the active site of protein kinases |
AU2004232308A1 (en) | 2003-04-23 | 2004-11-04 | Wyeth Holdings Corporation | PEG-wortmannin conjugates |
ES2586668T3 (es) | 2003-05-30 | 2016-10-18 | Gilead Pharmasset Llc | Análogos de nucleósidos fluorados modificados |
CA2529196A1 (en) | 2003-06-26 | 2005-02-17 | Merck & Co., Inc. | Benzodiazepine cgrp receptor antagonists |
US20080085902A1 (en) * | 2003-09-23 | 2008-04-10 | Guido Bold | Combination Of A Vegf Receptor Inhibitor Or With A Chemotherapeutic Agent |
EP1750715A1 (en) | 2004-06-04 | 2007-02-14 | Icos Corporation | Methods for treating mast cell disorders |
DE102004029784A1 (de) | 2004-06-21 | 2006-01-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel |
WO2006001266A1 (ja) | 2004-06-23 | 2006-01-05 | Banyu Pharmaceutical Co., Ltd. | 2-アリールプリン誘導体の製造方法 |
GB0420719D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
CN101065016A (zh) | 2004-09-24 | 2007-10-31 | 詹森药业有限公司 | 蛋白激酶的抑制剂咪唑并[4,5-b]吡嗪酮 |
CN101048410B (zh) | 2004-10-29 | 2010-06-23 | 泰博特克药品有限公司 | 抑制hiv的双环嘧啶衍生物 |
WO2006050076A1 (en) | 2004-10-29 | 2006-05-11 | Janssen Pharmaceutica, N.V. | Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders |
SE0403006D0 (sv) | 2004-12-09 | 2004-12-09 | Biovitrum Ab | New compounds |
US7767687B2 (en) | 2004-12-13 | 2010-08-03 | Biogen Idec Ma Inc. | Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as RAF kinase inhibitors |
EP1853588B1 (en) | 2005-02-16 | 2008-06-18 | AstraZeneca AB | Chemical compounds |
WO2006091737A1 (en) | 2005-02-24 | 2006-08-31 | Kemia, Inc. | Modulators of gsk-3 activity |
KR20080013886A (ko) | 2005-04-05 | 2008-02-13 | 파마코페이아, 인코포레이티드 | 면역억제용 퓨린 및 이미다조피리딘 유도체 |
LT2474545T (lt) * | 2005-12-13 | 2017-02-27 | Incyte Holdings Corporation | Heteroarilu pakeisti pirolo[2,3-b]piridinai ir pirolo[2,3-b]pirimidinai kaip janus kinazės inhibitoriai |
US20090281075A1 (en) | 2006-02-17 | 2009-11-12 | Pharmacopeia, Inc. | Isomeric purinones and 1h-imidazopyridinones as pkc-theta inhibitors |
ES2439590T3 (es) | 2006-08-02 | 2014-01-23 | Cytokinetics, Inc. | Ciertas entidades químicas, composiciones y métodos |
WO2008079460A2 (en) | 2006-09-05 | 2008-07-03 | Emory University | Tyrosine kinase inhibitors for prevention or treatment of infection |
US20100144738A1 (en) | 2006-09-05 | 2010-06-10 | William Bornmann | Inhibitors of c-met and uses thereof |
WO2008043031A1 (en) | 2006-10-04 | 2008-04-10 | Pharmacopeia, Inc. | 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression |
US7902187B2 (en) | 2006-10-04 | 2011-03-08 | Wyeth Llc | 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression |
KR101504669B1 (ko) | 2006-10-19 | 2015-03-20 | 시그날 파마소티칼 엘엘씨 | 헤테로아릴 화합물, 이들의 조성물 그리고 단백질 키나아제 억제제로서의 이들의 용도 |
BRPI0717773A2 (pt) | 2006-10-19 | 2013-11-05 | Signal Pharm Llc | Composto, composição farmacêutica, e, métodos para tratar ou prevenir câncer, uma condição inflamatória, uma condição imunológica ou uma condição metabólica, e para inibir uma quinase em uma célula que expressa a dita quinase |
AU2008345225A1 (en) | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
US20090258096A1 (en) | 2008-04-11 | 2009-10-15 | Bionovo, Inc. | Anticancer Methods Employing Extracts of Gleditsia sinensis Lam |
JP2011518219A (ja) * | 2008-04-22 | 2011-06-23 | ポートラ ファーマシューティカルズ, インコーポレイテッド | タンパク質キナーゼの阻害剤 |
US8110578B2 (en) | 2008-10-27 | 2012-02-07 | Signal Pharmaceuticals, Llc | Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway |
EP2379561B1 (en) | 2008-11-25 | 2015-11-04 | University Of Rochester | Mlk inhibitors and methods of use |
ES2613664T3 (es) | 2009-10-26 | 2017-05-25 | Signal Pharmaceuticals, Llc | Procedimientos de síntesis y purificación de compuestos de heteroarilo |
CN102821767A (zh) | 2010-02-03 | 2012-12-12 | 西格诺药品有限公司 | Lkb1突变作为对tor激酶抑制剂的敏感性的预测生物标记的鉴定 |
US20120028972A1 (en) | 2010-07-30 | 2012-02-02 | Lilly Wong | Biomarker assays for detecting or measuring inhibition of tor kinase activity |
CN105039520A (zh) | 2011-08-03 | 2015-11-11 | 西格诺药品有限公司 | 作为lkb1状态的预测性生物标志物的基因表达谱的鉴定 |
CN103814030A (zh) | 2011-09-22 | 2014-05-21 | 辉瑞大药厂 | 吡咯并嘧啶及嘌呤衍生物 |
BR112014009755B1 (pt) | 2011-10-19 | 2022-09-13 | Signal Pharmaceuticals, Llc | Tratamento de câncer com inibidores de quinase tor |
CA3125862A1 (en) | 2011-12-02 | 2013-06-06 | Signal Pharmaceuticals, Llc | Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use |
BR112014020786A2 (pt) | 2012-02-24 | 2020-10-27 | Signal Pharmaceuticals, Llc | método para tratamento de câncer de pulmão, método para alcançar um critério de avaliação de resposta em tumores sólidos, método para aumento da sobrevivência |
CA2866872A1 (en) | 2012-03-15 | 2013-09-19 | Signal Pharmaceuticals, Llc | Treatment of cancer with tor kinase inhibitors |
NZ628421A (en) | 2012-03-15 | 2016-04-29 | Signal Pharm Llc | Treatment of cancer with tor kinase inhibitors |
NZ628420A (en) | 2012-03-15 | 2016-04-29 | Signal Pharm Llc | Treatment of cancer with tor kinase inhibitors |
RU2645672C2 (ru) | 2012-08-06 | 2018-02-27 | Ацея Байосайенсиз Инк. | Новые соединения пирролопиримидина в качестве ингибиторов протеинкиназ |
AU2013203714B2 (en) | 2012-10-18 | 2015-12-03 | Signal Pharmaceuticals, Llc | Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity |
AU2013202768B2 (en) | 2012-10-18 | 2015-11-05 | Signal Pharmaceuticals, Llc | Treatment of cancer with TOR kinase inhibitors |
CN105188704B (zh) | 2013-01-16 | 2017-09-19 | 西格诺药品有限公司 | 被取代的吡咯并嘧啶化合物、其组合物和使用其的治疗方法 |
-
2015
- 2015-07-13 EA EA201790189A patent/EA201790189A1/ru unknown
- 2015-07-13 JP JP2017502145A patent/JP2017520603A/ja active Pending
- 2015-07-13 CA CA2955009A patent/CA2955009A1/en not_active Abandoned
- 2015-07-13 KR KR1020177003952A patent/KR20170024120A/ko unknown
- 2015-07-13 EP EP15822295.0A patent/EP3169686A4/en not_active Withdrawn
- 2015-07-13 US US14/797,548 patent/US9623028B2/en active Active
- 2015-07-13 CN CN201580049809.6A patent/CN106715427A/zh active Pending
- 2015-07-13 WO PCT/US2015/040125 patent/WO2016010886A1/en active Application Filing
- 2015-07-13 AU AU2015289929A patent/AU2015289929A1/en not_active Abandoned
-
2017
- 2017-03-08 US US15/452,816 patent/US20170173024A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20160008365A1 (en) | 2016-01-14 |
KR20170024120A (ko) | 2017-03-06 |
AU2015289929A1 (en) | 2017-03-02 |
WO2016010886A1 (en) | 2016-01-21 |
US9623028B2 (en) | 2017-04-18 |
US20170173024A1 (en) | 2017-06-22 |
JP2017520603A (ja) | 2017-07-27 |
CA2955009A1 (en) | 2016-01-21 |
EP3169686A4 (en) | 2018-01-24 |
CN106715427A (zh) | 2017-05-24 |
EP3169686A1 (en) | 2017-05-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201790189A1 (ru) | Способы лечения злокачественного новообразования с использованием замещенных пирролопиримидиновых соединений, композиции на их основе | |
EA201692203A1 (ru) | Соединения, ингибирующие tank-связывающую киназу | |
EA201890857A1 (ru) | Соединения, применимые в качестве иммуномодуляторов | |
EA201691857A1 (ru) | Соединения, применимые в качестве иммуномодуляторов | |
EA201892229A1 (ru) | Замещенные аминопуриновые соединения, содержащие их композиции и способы лечения с их применением | |
EA201690406A1 (ru) | Селективные ингибиторы grp94 и способы их применения | |
EA201692526A1 (ru) | Замещенные [1,2,4]триазольные соединения | |
EA201692219A1 (ru) | Способы получения противовирусных соединений | |
MX2016002544A (es) | Compuestos utiles como inmunomoduladores. | |
EA201890754A1 (ru) | Соединения и способы их применения | |
EA201591327A1 (ru) | Замещенные пирролопиримидиновые соединения, их композиции и способы лечения с использованием таких соединений | |
EA201891336A1 (ru) | Гетероарилгидроксипиримидиноны в качестве агонистов рецептора apj | |
EA201690473A1 (ru) | Комбинированный состав двух противовирусных соединений | |
EA201591728A1 (ru) | Гетероциклические соединения и способы их применения | |
EA201590997A1 (ru) | Соединения и способы их применения | |
EA201591705A1 (ru) | Композиции и способы для диагностики и лечения рака печени | |
EA201592068A1 (ru) | Ингибиторы энхансера zeste гомолога 2 | |
MX2016011897A (es) | Composiciones de compuestos selenoorganicos y metodos de uso de los mismos. | |
BR112017005266A2 (pt) | inibidores de mk2 e uso dos mesmos | |
EA201690764A1 (ru) | Ингибитор грелин-o-ацилтрансферазы | |
EA201692525A1 (ru) | Замещенные соединения [1,2,4]триазола и имидазола в качестве фунгицидов | |
EA201500801A1 (ru) | Бензохинолоновые ингибиторы vmat2 | |
EA201692548A1 (ru) | Минеральные аминокислотные комплексы активных веществ | |
EA201690844A1 (ru) | Ингибиторы gsk-3 | |
EA201692204A1 (ru) | Композиции и способы модулирования экспрессии фактора комплемента b |